Dr. Paraskevi Giannakakou

In its eighth year, the annual Dean's Symposium on Innovation and Entrepreneurship celebrates innovation and Weill Cornell Medicine’s entrepreneurial spirit, while encouraging and motivating the next generation of innovators, inventors and entrepreneurs.

A new protein variant underlies the ability of gastric cancers to resist an otherwise effective family of chemotherapy drugs, according to a study by a multidisciplinary team at Weill Cornell Medicine. The results suggest a treatment strategy that could improve the prognoses of many patients with cancer.

Weill Cornell Medicine scientists have developed a machine-learning algorithm capable of predicting biological targets of prospective drug molecules.